Fedorova O V, Shadrin G B
L.I. Sverzhevsky Research Clinical Institute of Otorhinolaryngology, Moscow Health Department, Moscow, Russia, 117152.
Vestn Otorinolaringol. 2016;81(3):51-53. doi: 10.17116/otorino201681351-53.
The objective of the present study was to evaluate the clinical effectiveness and safety of the local application of triderm for the treatment of diffuse external otitis. The study included 68 patients presenting with bacterial and fungal diffuse external otitis. The treatment in the form of local empiric therapy was continued till the results of microbiological treatment became apparent. The beneficial outcome achieved in 91.2% of the patients was clinically manifest as the regression of the inflammatory process in the external auditory meatus. No complications, such as ototoxic events, either local or systemic allergic reactions, were documented. The authors substantiate the possibility of the application of the medication under consideration for the treatment of diffuse external otitis based on the knowledge of the mechanism of the actin of its constituent components, viz. betamethasone, dipropionate, gentamicin sulfate, and clotrimazole, taking into account the occurrence of the most common causative agents of diffuse external otitis. It is concluded that triderm is a safe medication for the local application and, probably, for the initial empiric therapy of diffuse external otitis to be continued till the results of the microbiological treatment become apparent.
本研究的目的是评估曲安奈德益康唑乳膏局部应用治疗弥漫性外耳道炎的临床有效性和安全性。该研究纳入了68例患有细菌性和真菌性弥漫性外耳道炎的患者。以局部经验性治疗的形式持续治疗，直到微生物治疗结果显现。91.2%的患者取得了有益的结果，临床上表现为外耳道炎症过程消退。未记录到任何并发症，如耳毒性事件、局部或全身过敏反应。作者基于对其组成成分（即倍他米松二丙酸酯、硫酸庆大霉素和克霉唑）作用机制的了解，并考虑到弥漫性外耳道炎最常见病原体的发生情况，证实了考虑使用该药物治疗弥漫性外耳道炎的可能性。结论是，曲安奈德益康唑乳膏是一种局部应用安全的药物，可能适用于弥漫性外耳道炎的初始经验性治疗，并持续至微生物治疗结果显现。
